Agomab Therapeutics, a clinical-stage biotech developing treatments for fibrotic diseases, has raised approximately $200 million through a public offering on the Nasdaq stock exchange. The February 9 listing values the Antwerp-based company at roughly $780 million and provides capital to advance its lead program targeting fibrostenosing Crohn's disease into pivotal trials.
The company is focused on inflammatory and immunological conditions where fibrosis—the excessive buildup of scar tissue—drives progressive organ damage. This therapeutic area has attracted significant pharmaceutical industry interest, with Agomab previously securing investments from Pfizer, Sanofi, and Boehringer Ingelheim, as well as major life sciences investors Fidelity and EQT Life Sciences.
Funding for a focus on fibrosis
Agomab has announced that the company plans to use IPO proceeds to support a global Phase 2b study in fibrostenosing Crohn’s disease — a severe form of Crohn’s where scarring can narrow the bowel and often lead to surgery.
Its most advanced candidate, ontunisertib (AGMB-129), is an oral, gut-restricted inhibitor of ALK5 (TGFβR1) designed to target fibrotic signaling locally in the intestine. This combination — a pill for a chronic condition with a high unmet need for targeted treatments — is obviously one of the things about Agomab that has caught investor attention.
Agomab’s broader pipeline also includes AGMB-447, a lung-targeted ALK5 inhibitor in early clinical development for idiopathic pulmonary fibrosis (IPF), and AGMB-101, an HGF-mimetic antibody in preclinical testing, designed to activate the MET receptor in a pathway linked to tissue repair.
A Billion-dollar Biotech Week
Agomab’s debut lands in an unusually busy week for biotech IPOs, with several offerings adding up to over $1 billion in proceeds. This includes the year’s biggest biotech listing so far from cancer-focused Eikon Therapeutics, alongside newly priced deals from SpyGlass Pharma and Veradermics.
For Belgium’s life sciences ecosystem, the listing is a notable milestone. Antwerp-based Agomab is a Biovia member company, and it is also a V-Bio Ventures portfolio company. This underscores the strength of the local venture and cluster network, which supports companies like Agomab that scale from Flanders to global capital markets.
Along with Ghent-based Argenx, Agomab has clearly become one of Belgium’s most rapidly rising stars in health innovation — a company to keep an eye on.
Bron: BioVox